Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 120Carcinoma, Non-Small-Cell Lung 107Prostatic Neoplasms 92Multiple Myeloma 77Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Pancreatic Neoplasms 39Melanoma 39Lymphoma 39Lymphoma, Non-Hodgkin 38Carcinoma, Renal Cell 38Ovarian Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 32Urinary Bladder Neoplasms 31Hematologic Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Endometrial Neoplasms 28Uterine Cervical Neoplasms 26Triple Negative Breast Neoplasms 25Carcinoma, Hepatocellular 25Sarcoma 24Glioma 24Brain Neoplasms 24Stomach Neoplasms 23Recurrence 22Head and Neck Neoplasms 22

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rhabdomyosarcoma, Alveolar × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡